Abstract
Social dynamics are an integral part of the spread of disease affecting contact rates as well as the adoption of pharmaceutical and non-pharmaceutical interventions. When vaccines provide waning immunity, efficient and timely uptake of boosters is required to maintain protection and flatten the curve of infections. How then do social dynamics affect the timely up-take of vaccines and thereby the course of an epidemic? To explore this scenario, a behavioural-epidemiological is developed here. It features a tipping-point dynamic for the uptake of vaccines that combines the risk of infection, perceived morbidity risk of the vaccine, and social payoffs for deviating from the vaccination decision making of others. The social payoffs are derived from a social norm of conformity, and they create a collective action problem. A key finding driven by this dilemma is that waves of vaccine uptake and infections can occur due to inefficient and delayed uptake of boosters. This results in a nonlinear response of the infection load to the transmission rate: an intermediate transmission rate can result in greater prevalence of disease relative to more or less transmissible diseases. Further, global information about the prevalence of the disease and vaccine uptake increases the infection load and peak relative to information restricted to individuals’ contact net-works. Thus, decisions driven by local information can mitigate the collective action problem across the population. Finally, the optimal public policy program to promote boosters is shown to be one that focuses on overcoming the social inertia to vaccinate at the start of an epidemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
bmorsky{at}fsu.edu
Data Availability
There is no data to report.